BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 15341706)

  • 1. Extended treatment for venous thromboembolism: how long is long enough?
    Cosmi B; Palareti G
    Curr Hematol Rep; 2004 Sep; 3(5):375-81. PubMed ID: 15341706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral anticoagulant therapy in venous thromboembolism.
    Cosmi B; Palareti G
    Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current criteria to determine the duration of anticoagulant therapy].
    Palareti G
    Recenti Prog Med; 2007 Dec; 98(12):603-6. PubMed ID: 18369033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
    Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Minar E; Lechner K; Kyrle PA
    Thromb Haemost; 1997 Apr; 77(4):624-8. PubMed ID: 9134632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term management of patients after venous thromboembolism.
    Kearon C
    Circulation; 2004 Aug; 110(9 Suppl 1):I10-8. PubMed ID: 15339876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous thromboembolism: risk factors for recurrence.
    Zhu T; Martinez I; Emmerich J
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
    Santamaria MG; Agnelli G; Taliani MR; Prandoni P; Moia M; Bazzan M; Guazzaloca G; Ageno W; Bertoldi A; Silingardi M; Tomasi C; Ambrosio GB;
    Thromb Res; 2005; 116(4):301-6. PubMed ID: 16038714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia.
    Palareti G; Legnani C; Cosmi B; Valdré L; Lunghi B; Bernardi F; Coccheri S
    Circulation; 2003 Jul; 108(3):313-8. PubMed ID: 12847064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.
    Wåhlander K; Eriksson H; Lundström T; Billing Clason S; Wall U; Nyström P; Wessman P; Schulman S;
    Br J Haematol; 2006 Apr; 133(1):68-77. PubMed ID: 16512831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin.
    Brouwer JL; Lijfering WM; Ten Kate MK; Kluin-Nelemans HC; Veeger NJ; van der Meer J
    Thromb Haemost; 2009 Jan; 101(1):93-9. PubMed ID: 19132194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of anticoagulant therapy after initial idiopathic venous thromboembolism.
    Frazee LA; Chomo DL
    Ann Pharmacother; 2003 Oct; 37(10):1489-96. PubMed ID: 14519045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of recurrent idiopathic venous thromboembolism.
    Goldhaber SZ
    Circulation; 2004 Dec; 110(24 Suppl 1):IV20-4. PubMed ID: 15598644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D-dimer, oral anticoagulation, and venous thromboembolism recurrence.
    Cosmi B; Palareti G
    Semin Vasc Med; 2005 Nov; 5(4):365-70. PubMed ID: 16302157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should patients with venous thromboembolism be screened for thrombophilia?
    Dalen JE
    Am J Med; 2008 Jun; 121(6):458-63. PubMed ID: 18501222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The optimal duration of anticoagulation in patients with venous thromboembolism: how long is long enough?
    Prandoni P; Piovella C; Spiezia L; Dalla Valle F; Pesavento R
    Panminerva Med; 2012 Mar; 54(1):39-44. PubMed ID: 22278115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
    Farraj RS
    Saudi Med J; 2004 Jul; 25(7):848-51. PubMed ID: 15235686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model.
    Eichinger S; Heinze G; Jandeck LM; Kyrle PA
    Circulation; 2010 Apr; 121(14):1630-6. PubMed ID: 20351233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of thrombophilia in deciding on the duration of anticoagulation.
    Bauer KA
    Semin Thromb Hemost; 2004 Dec; 30(6):633-7. PubMed ID: 15630669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overweight, obesity, and the risk of recurrent venous thromboembolism.
    Eichinger S; Hron G; Bialonczyk C; Hirschl M; Minar E; Wagner O; Heinze G; Kyrle PA
    Arch Intern Med; 2008 Aug; 168(15):1678-83. PubMed ID: 18695082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for venous thromboembolism in children.
    Gerotziafas GT
    Int Angiol; 2004 Sep; 23(3):195-205. PubMed ID: 15765033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.